Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Should You Sell This Stock Following a Regulatory Roadblock?

TheMotleyFool 
0 0 05.04.24
Should You Sell This Stock Following a Regulatory Roadblock?: https://g.foolcdn.com/editorial/images/770862/physician-talking-to-patient.jpg
 

Biotech giant Regeneron Pharmaceuticals (NASDAQ: REGN) has been on fire over the past three years. The company has delivered solid clinical progress and an important regulatory approval, and its financial results have generally been robust excluding its coronavirus antibody, whose sales are dropping.

However, every company, even the best ones, sometimes encounters headwinds. Regeneron is no exception. The drugmaker recently received a rejection letter from U.S. regulators regarding an application it submitted for one of its pipeline candidates. Let's look at what this means for the business and its shareholders.

REGN Total Return Level Chart

Continue reading


Source Fool.com

Regeneron Pharmaceuticals Inc. Stock

€845.00
1.220%
There is an upward development for Regeneron Pharmaceuticals Inc. compared to yesterday, with an increase of €10.20 (1.220%).
With 34 Buy predictions and 1 Sell predictions Regeneron Pharmaceuticals Inc. is one of the favorites of our community.
As a result the target price of 957 € shows a slightly positive potential of 13.25% compared to the current price of 845.0 € for Regeneron Pharmaceuticals Inc..
Show more
Like: 0
REGN
Share

Comments

Not a member yet? Sign up for free!